Story perspectives

UK's £10.7M Study on Puberty Blockers Sparks Controversy

11/30/2025

Summary

Story summary

The Pathways trial, an NHS study in the United Kingdom, will study puberty blockers in 10–15-year-olds with gender dysphoria.
The trial will enroll 250 participants, with more than half receiving hormone-suppressing medication, in a £10.7 million project.
Researchers from King's College London will assess health impacts, including skeletal and neurological development.
Critics, including Dr. Louise Irvine, say the inclusion of "two-spirit" in the gender identity survey reflects bias.

1 of 1

Story summary

The Pathways trial, an NHS study in the United Kingdom, will study puberty blockers in 10–15-year-olds with gender dysphoria.
The trial will enroll 250 participants, with more than half receiving hormone-suppressing medication, in a £10.7 million project.
Researchers from King's College London will assess health impacts, including skeletal and neurological development.
Critics, including Dr. Louise Irvine, say the inclusion of "two-spirit" in the gender identity survey reflects bias.